1. Introduction {#sec1}
===============

Sepsis is one of the main causes of mortality among neonates worldwide. The incidence of neonatal sepsis in the United States is approximately two per 1000 live births \[[@bib10]\]. The aim of a study conducted in Saudi Arabia was to determine the overall incidence of neonatal sepsis in very low birth weight (VLBW) infants born in one of the university hospitals in Riyadh during 1999--2007. The rate of neonatal sepsis in VLBW infants was 48%. Neonatal sepsis is a very complex type of neonatal infection that affects newborns, where infants suffer from bloodstream infections (BSIs). The percentage of neonatal deaths due to life-threatening BSIs in developing countries has reached 99%, with a total of 1 million annual deaths \[[@bib1]\]. In 2014, neonatal sepsis prevalence reached 48% in Saudi Arabia \[[@bib2]\]. Neonatal sepsis is categorized as early-onset sepsis (EOS) and late-onset sepsis (LOS) according to age \[[@bib3],[@bib4]\]. EOS is a maternal vertical transmission of bacterial pathogens to the infant occurring in the first 3 days of the infant\'s life \[[@bib3]\], whereas LOS is the horizontal transmission of pathogens from the environment occurring after 7 days of an infant\'s life \[[@bib4], [@bib5], [@bib6]\]. In neonatal intensive care units (NICUs), antibiotics are the most commonly prescribed treatment. For treatment, empiric antibiotics are administered in the first postnatal days to infants with extremely low birth weight. The duration of the initial empiric antibiotic treatment course plays an important factor in neonatal sepsis therapy \[[@bib5]\]. In case of suspected LOS, rapid initiation of treatment with empiric antibiotics is important; however, prolonged and unnecessary antibiotic use may lead to adverse outcomes in neonates. In some cases, owing to previous treatment with antibiotics or small blood volume, the result of blood cultures is negative and the decision to continue or discontinue antibiotic treatment depends on the case. Nevertheless, prolonged treatment with broad-spectrum antibiotics in case of a negative culture result can be associated with increased risks of necrotizing enterocolitis (NEC) or death \[[@bib6], [@bib7], [@bib8], [@bib9]\]. The aim of this study was to assess any association between the duration of antibiotic treatment for neonatal sepsis and other factors including comorbidities, interventions, and adverse outcomes.

2. Methods {#sec2}
==========

2.1. Study design {#sec2.1}
-----------------

This was a retrospective cohort study in which infants with suspected EOS were admitted in the NICU of King Saud Medical City from July 2015 to June 2017. This study followed the principles of the Declaration of Helsinki, in accordance with the Medical Research Involving Human Subjects Act (WMO) and was approved by the medical ethical review committee of our institution.

We conducted the study on 323 neonates with suspected EOS; the infants received empiric antibiotic treatment, and a standardized questionnaire was used to collect information about maternal and neonatal parameters. We classified the dataset according to the duration of the antibiotics administered: premature neonates who received antibiotic treatment for 5 days or less and those who received antibiotic treatment for more than 5 days.

All neonates were inborn, with age less than or equal to 180 days; were admitted to our NICU; and received antibiotic treatment. Outborn neonates, those who did not receive antibiotics, those with postpartum age of more than 180 days, and those with major congenital anomalies were excluded from the study. We followed up all neonates until their discharge, transfer, or death.

The primary outcome measures were the association between the antibiotic treatment duration and maternal factors, gender, adverse outcomes, developmental factors, comorbid conditions, EOS, and LOS.

We conducted all statistical tests at a confidence level of 95%. We used SPSS software (Statistical Package for the Social Sciences, version 20.0, SSPS Inc., Chicago, IL, USA) for statistical analyses, and we represented numerical data as mean and standard deviation or median and interquartile range and categorical data as frequency (count) and relative frequency (percentage).

To compare categorical data, we performed a chi-square test or Phi--Cramer test and used the exact test instead when the expected frequency was less than 5. We made comparisons between quantitative variables using the Student t-test and the nonparametric Mann--Whitney test when needed, and we considered *P* values less than 0.05 as statistically significant.

Univariate analysis comparing different characteristics between survivors and nonsurvivors was conducted using an independent *t*-test for normally distributed data and the Mann--Whitney *U* test for skewed data. We used a χ2 test to compare differences in survival for categorical variables. Variables with a *P* value \< .05 in the univariate analysis were entered into a multiple stepwise logistic regression model to establish predictors of mortality.

3. Results {#sec3}
==========

The number of infants included in the dataset was 323; as we were unable to retrieve records for 28 infants, the study included 295 infants; 28 neonates were excluded. Of the 28 infants excluded, 16 of them were outborn, six did not receive antibiotic treatment, five had major congenital anomalies, and one was outborn and had major congenital anomalies, thus leaving 295 cases included in the analysis. The number of infants with antibiotic treatment duration of 5 days or less was 104 and that of infants with duration of more than 5 days was 191.

3.1. Baseline characteristics {#sec3.1}
-----------------------------

Out of 295 infants, 153 (51.9%) of them were males and 142 (48.1%) were females. Fifty-three mothers (18%) went for a follow-up at the perinatology clinic before delivery. One hundred thirty-six infants (46.1%) were delivered by spontaneous vaginal delivery (SVD), whereas the others (159; 53.9%) were delivered by cesarean section (CS). Additionally, 27 (9.2%) infants had intrauterine growth restriction (IUGR; [Table 1](#tbl1){ref-type="table"}).Table 1Baseline characteristics.Table 1ValidMissedNumber of infants with the condition (%)n% of total**Follow up by the perinatology clinic before delivery**2950Yes5318.00No24282.00**Mode of delivery**2950SVD13646.10CS15953.90**Gender**2950Male15351.90Female14248.10**Intrauterine growth restriction (IUGR)**2950Yes279.20No26890.80**Extreme prematurity**2950Yes9933.70No19566.30**Respiratory distress syndrome**2950Yes28195.30No144.70**Pneumothorax**2950Yes165.40No27994.60**Pulmonary hemorrhage**2950Yes26890.80No279.20**Patent ductus arteriosus**2950Yes12341.70No17258.30**Intraventricular hemorrhage**2950Yes7324.70No22275.30**Periventricular leukomalacia**2950Yes258.50No27091.50**Umbilical arterial catheter**2950Yes10736.30No18863.70**Central line: UVC**2950Yes22475.90No7124.10**Central line: CVC**2950Yes62.00No28998.00**Central line: PICC**2950Yes5318.00No24282.00**Type of sepsis**2950EOS51.70LOS5418.30**Positive blood culture**2950Yes5719.30No23880.70**Bacterial resistance**650Yes3249.20No3350.80**Candidiasis**2950Yes20.70No29399.30**Necrotizing enterocolitis**2950Yes10234.60No19365.40**Mortality**2950Yes6421.70No23178.30

3.2. Antibiotic duration {#sec3.2}
------------------------

Gender, developmental factors, and maternal factors:

The duration of antibiotic treatment was not associated with gender, IUGR, or extreme prematurity. The number of males who received antibiotic treatment for 5 days or less and for more than 5 days were 54 (35.3%) and 99 (64.7%), respectively, and for females, it was 50 (35.2%) and 92(64.8%), respectively. Differences among these groups were, however, not statistically significant (*P* = .988). For premature neonates who had IUGR, five (18.5%) of them received antibiotic treatment for 5 days or less and 22 (81.5%) of them received the treatment for more than 5 days (*P* = .056) ([Table 2](#tbl2){ref-type="table"}).Table 2Gender, developmental factors and maternal factors.Table 2ValidMissedDuration of antibiotics*P* valueFive daysMore thanor lessfive days**n%n%**Gender2950Male5435.39964.7.988Female5035.29264.8Intrauterine growth restriction (IUGR)2950.056Yes518.52281.5No9936.916963.1Extreme prematurity2950.391Yes3838.46161.6No6533.313066.7Follow up by the perinatology clinic before delivery2950Yes2241.53158.5.293No8233.916066.1Mode of delivery2950SVD5339.08361.0.217CS5132.110867.9

3.3. Comorbid conditions {#sec3.3}
------------------------

Among the comorbidities, the percentage of infants with respiratory distress syndrome (95.30%) and pulmonary hemorrhage (90.80%) was high. There was an association between the presence of patent ductus arteriosus (PDA), intraventricular hemorrhage (IVH), and periventricular leukomalacia (PVL) and the duration of antibiotic treatment. Twenty-three (18.7%) out of 295 infants with PDA received the antibiotic treatment for 5 days or less and 100 (81.3%) of them received the treatment for more than 5 days (*P* \< .001). Among the 73 infants who had IVH, there was statistically significant difference (*P* \< .001) between those who received the treatment for 5 days or less (13; 17.8%) and those who received the treatment for more than 5 days (60; 82.2%). The total number of infants with PVL was 25, where four (16%) of them received antibiotic treatment for 5 days or less and 21 (84%) of them were treated for more than 5 days (*P* = .035) ([Table 1](#tbl1){ref-type="table"}, [Table 3](#tbl3){ref-type="table"}).Table 3Comorbid conditions and duration of antibiotics.Table 3ValidMissedDuration of antibiotics*P* valueFive daysMore thanor lessfive days**n%n%**Respiratory distress syndrome2950.588Yes9935.218264.8No535.7964.3Pneumothorax2950.73Yes531.31168.8No9935.518064.5Pulmonary hemorrhage2950.827Yes9535.417364.6No933.31866.7Patent ductus arteriosus2950\<.001Yes2318.710081.3No8147.19152.9Intraventricular hemorrhage2950\<.001Yes1317.86082.2No9141.013159.0Periventricular leukomalacia2950.035Yes416.02184.0No10037.017063.0

3.4. Interventional factors {#sec3.4}
---------------------------

Umbilical vein catheter (UVC) and peripherally inserted central catheter (PICC) were associated with the duration of antibiotic treatment. Among the infants who underwent UVC (n = 224/295, 75.9%), a significant difference (*P* = .047) was observed between the percentage of those who received the treatment for 5 days or less (72; 32.1%) and who received the treatment for more than 5 days (152; 67.9%). Infants who underwent PICC were 53, among which three (5.7%) received the treatment for 5 days or less and 50 (94.3%) received the treatment for more than 5 days (*P* \< .001). It was observed that the use of PICC and UVC was not associated with the duration of antibiotic treatment (*P* = .944).

3.5. Adverse outcomes {#sec3.5}
---------------------

LOS was associated with the duration of early empiric antibiotic use. Among infants with LOS (n = 54/295), four (7.4%) of them received antibiotic treatment for 5 days or less and 50 (92.6%) of them received antibiotic treatment for more than 5 days (*P* \< .001). In addition, both positive blood culture result (*P* \< .001) and bacterial resistance (*P* = .013) were associated with the duration of antibiotic treatment. Approximately 91.2% of those receiving treatment for prolonged duration had positive blood culture result, and all the infants with bacterial resistance were receiving prolonged therapy. NEC was more prevalent in those with a long duration of antibiotic treatment (95.1%) than in those with a short duration of treatment (*P* \< .001). Candidiasis was insignificantly (*P* \> .05) more prevalent in those with a long duration of antibiotic treatment ([Table 4](#tbl4){ref-type="table"}) than in those with a short duration of treatment. The survival percentage reached 78.3%, among which 70% had a prolonged duration of antibiotic therapy.Table 4Adverse outcomes.Table 4ValidMissedDuration of antibiotics*P* valueFive days or lessMore than five daysn%n%**Type of sepsis**2950EOS120.0480.0.66LOS47.45092.6 \< **.001Positive blood culture**2950 \< **.001**Yes58.85291.2No9941.613958.4**Bacterial resistance**650**.013**Yes00.032100.0No618.22781.8**Candidiasis**2950.418Yes00.02100.0No10435.518964.5**Necrotizing enterocolitis**2950 \< **.001**Yes54.99795.1No9951.39448.7**Mortality**2950 \< **.001**Yes3656.32843.7No6829.416370.6

3.6. Other factors {#sec3.6}
------------------

Data of premature neonates who received antibiotics for 5 days or less and those who received antibiotics for more than 5 days with regard to hospital stay in days were mean (SD) 2811.5 (14) and median (IQR) 4 (16). There was also a significant difference between those who received antibiotics for 5 days or less and those who received antibiotics for more than 5 days with regard to blood loss (*P* = .003), packed RBC transfusion (*P* \< .001), platelet transfusion (*P* \< .001), or fresh frozen plasma transfusion (*P* = .007; [Table 5](#tbl5){ref-type="table"}).Table 5Other factors.Table 5ValidMissedFive days or lessMore than five days*P* valueMean (SD)Median (IQR)Mean (SD)Median (IQR)Gestational age in weeks2771828.9 (3.6)29 (6)29.5 (3.1)29.5 (4).232Birth weight277181133.7 (337.2)1170 (585)1130.1 (266.2)1137.5 (419).864Hospital stay in days2771811.5 (14)4 (16)46.5 (29.3)43 (42.5) \< **.001**Temperature2771836.1 (0.9)36.4 (0.6)36.1 (2.8)36.3 (0.7).379Blood loss at week 1 per Kg body weight277181.9 (5.3)0 (0)6 (12)0 (8.94)**.003**Packed RBCs transfusion277180.5 (0.9)0 (1)3.1 (3.7)2 (5) \< **.001**Platelets transfusion277180 (0.2)0 (0)1.2 (3.1)0 (1) \< **.001**Fresh frozen plasma transfusion277180.2 (0.5)0 (0)0.7 (1.7)0 (1)**.007**

4. Discussion {#sec4}
=============

The main objective of the study was to assess the association between the duration of early empiric antibiotic treatment for suspected neonatal sepsis and other factors including comorbidities, interventions, and adverse outcomes. Prolonged treatment with empiric antibiotics is associated with adverse outcomes including invasive candidiasis, increased antimicrobial resistance, NEC, LOS, and death. However, the choice of antibiotic or duration of empiric antibiotic treatment is often not associated with risk factors for sepsis \[[@bib8]\]. Our study was conducted for a period of 24 months. The total number of the population with suspected neonatal sepsis admitted to the NICU was 323.

Throughout the study, a higher percentage of infants with PDA, IVH, and PVL received antibiotic treatment for more than 5 days. Our data showed that prolonged treatment with antibiotics is associated with increased risk of NEC and death. Results showed that prevalence of infants with NEC reached 95.1% within the study population. The study conducted by Michael Cotten et al. \[[@bib5]\] assessed the association between the duration of the initial antibiotic course and subsequent NEC or death among 5693 ELBW infants across 19 centers. They reported that 4039 infants survived (71%), 2147 of which (53%) had received prolonged (\>5 days) empiric antibiotic treatment \[[@bib5]\]. On the other hand, our study showed that 70% of premature infants who survived were on prolonged treatment of antibiotics.

In the multicenter study by Ying Dong \[[@bib4]\], 5693 ELBW infants with sterile cultures started empiric antibiotic treatment within the first 3 days postdelivery; the initial median duration of empiric antibiotic treatment was 5 (3--9.5) days. Additionally, the study revealed that each additional day of antibiotic treatment was accompanied by increased risk of NEC or death, which accounts to an increase by 7% in NEC and by 16% in death \[[@bib4]\]. A multicenter retrospective cohort study examined 790 ELBW infants with regard to the duration of empiric antibiotic therapy for EOS. The dataset was classified into two groups: infants who received ≤3 days of empiric antibiotic therapy and those who received ≥7 days. Out of the total population, 695 infants had negative culture results, among which 40% received ≤3 days of therapy and 34% received ≥7 days of therapy \[[@bib7]\].

In a retrospective cohort study conducted by Venkata S. kuppala et al., of the 365 infants who survived 7 days free from NEC or sepsis, 36% had received prolonged initial empiric antibiotic treatment. Approximately 17 infants (4.6%) were diagnosed with NEC and 20 (5.5%) died. Moreover, they found that 76 (21%) infants in the study population had LOS. LOS, NEC, or death occurred more frequently in the group that received prolonged antibiotic treatment than in the limited antibiotic treatment group \[[@bib9]\]. In our study, LOS was also associated with prolonged antibiotics therapy (\>5 days); among LOS infants, 50 (92.6%) received antibiotic treatment for more than 5 days. In another study by Sobaih et al. \[[@bib2]\], the rate of neonatal sepsis in VLBW infants was found to be high (48%) with high rates of both EOS and LOS. This necessitates highly prioritizing the prevention and control of sepsis \[[@bib2]\].

To conclude, both positive blood culture result and bacterial resistance were associated with the duration of early empiric antibiotic treatment. There was also an association between prolonged antibiotic treatment (\>5 days) and comorbid conditions (PDA, IVH, and PVL). However, no association with other adverse outcomes such as candidiasis or maternal factors was found.
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